JAMP Pharma Group announces the appointment of a new Chief Operating Officer
Marie-Sophie Tremblay’s new role underlines the Group’s commitment to operational excellence following the announcement of the acquisition of a pharmaceutical manufacturing site in Quebec and the resumption of operations for medication production.
Boucherville, Quebec – October 7, 2024 – JAMP Pharma Group, a Canadian pharmaceutical organization established as an industry leader, is proud to announce the appointment of Marie-Sophie Tremblay as Chief Operating Officer (COO). Marie-Sophie’s appointment to this position will strengthen JAMP Pharma Group’s operations management team, at a time marked by the re-launch of the Lévis manufacturing site acquired last February.
“Marie-Sophie stands out for her passion for people, and her seasoned track record in operational excellence,” said Louis Pilon, CEO of JAMP Pharma Group. I am confident that she will play a key role in the continued growth of JAMP Pharma Group and our ambition to manufacture high-quality pharmaceutical products in Quebec, through our new division, Fabrication JAMP Pharma.”
In her new role, Marie-Sophie Tremblay will be responsible for overseeing all JAMP Pharma Group operations, ensuring the efficiency and quality of products and service levels. Marie-Sophie will be responsible for managing the supply chain, information technology and JAMP Pharma Manufacturing. Her expertise will be invaluable in consolidating JAMP Pharma Group’s leading position in the Canadian pharmaceutical market.
“It’s an honor for me to take the reins of JAMP Pharma Group’s operations and work alongside such dedicated people with a culture of excellence,” added Marie-Sophie-Tremblay, Chief Operating Officer of JAMP Pharma Group. “I look forward to working with the various teams and actively participating in this adventure to make the Lévis facility a production site at the cutting edge of pharmaceutical technology.”
Prior to joining JAMP Pharma Group, Marie-Sophie Tremblay spent a large part of her career in Europe and the United States in various sectors such as manufacturing, supply chain, product portfolio management and information technology. She has experience in various executive positions, mainly in the consumer products and food processing industries. In recent years, she has held the position of Vice-President, Business Process Transformation at Agropur, where she led the transformation of the cooperative through business process re-engineering and the implementation of an enterprise-wide ERP system. Her expertise focuses on organizational development, innovative practices and operational excellence. A graduate in Engineering Physics from Université Laval, she completed the McGill – HEC Montréal Executive MBA program.
About JAMP Pharma Group
JAMP Pharma Group is a Canadian organization headquartered in Boucherville, in the greater Montreal area. Having experienced exceptional growth over the past 10 years, JAMP Pharma Group is present in all segments of the pharmaceutical market, with a portfolio of over 350 molecules, and is one of the industry leaders in terms of annual prescription volume1. With over 130 new products authorized for sale by Health Canada in the last three years, JAMP Pharma Group is the Canadian leader in product launches2, enhancing the new treatment options available in Canada, including many specialty drugs. The addition of a new local manufacturing site and a new division, JAMP Pharma Manufacturing, supports JAMP Pharma Group’s vision of becoming the largest Canadian-owned pharmaceutical company.
In addition to its generic division, JAMP Pharma Group has several divisions such as Orimed, BioJAMP, Wampole, Laboratoire Suisse and Cosmetic Import, also offering prescription and branded products, biosimilar products, 180 over-the-counter products with a diverse range of vitamins, supplements and natural health products. The JAMP CareTM patient support program is designed to assist patients, as well as healthcare professionals, in taking the specialty drugs and biosimilars offered by the JAMP Pharma Group.
Information
Alexandra Lewicki – Senior Director, Marketing and Communications
1 Source: based on internal data.
2 Source: based on internal data.